Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Peripheral blood mononuclear cell collection protocol for tumor immunotherapy study of UCAR-T cells

  • 0 views
  • 05 Aug, 2020
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.

follicle stimulating hormone
bilateral salpingectomy
tremelimumab
non-small cell lung cancer
lung neoplasm
  • 0 views
  • 16 Feb, 2024
  • 1 location
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow …

hormone replacement therapy
follicle stimulating hormone
neutrophil count
monoclonal antibody therapy
major surgery
  • 0 views
  • 05 Aug, 2020
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow …

non-small cell lung cancer
neutrophil count
lung cancer
monoclonal antibodies
stereotactic body radiation
  • 0 views
  • 16 Feb, 2024
  • 22 locations
Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC. The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.

adjuvant
immunomodulators
carcinoma of the cervix
salvage therapy
lung cancer
  • 0 views
  • 05 Aug, 2020